Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy

Authors: Harrington, K., Cohen, E., Siu, L., Rischin, D., Licitra, L., Vermorken, J., Le, Q.T., Tahara, M., Machiels, J.P., Hawk, N., Ge, J., Bidadi, B., Swaby, R., Burtness, B.

Source: International journal of radiation oncology, biology, physics. 112(5):e43-e44

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100157352084.0x000001&indx=1&recIds=ETOCvdc_100157352084.0x000001

316TiPNeoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study

Authors: Cohen, E, Uppaluri, R, Lee, N, Westra, W, Haddad, R, Temam, S, Le Tourneau, C, Chernock, R, Safina, S, Tao, Y, Klochikhin, A, Meirovitz, A, Brana, I, Ge, J Y, Swaby, R, Bidadi, B, Adkins, D

Source: Annals of oncology. 30(9)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100096983228.0x000001&indx=1&recIds=ETOCvdc_100096983228.0x000001

LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

Authors: Machiels, J-P., Tao, Y., Burtness, B., Tahara, M., Rischin, D., Alves, G.V., Lima, I.P.F., Hughes, B.G.M., Pointreau, Y., Aksoy, S., Laban, S., Greil, R., Burian, M., Hetnal, M., Licitra, L.F., Swaby, R., Zhang, Y., Gumuscu, B., Bidadi, B., Siu, L.L.

Source: In Annals of Oncology September 2022 33 Supplement 7:S1399-S1399

443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)

Authors: Gaspar, N., Campbell-Hewson, Q., Bielack, S.S., Campbell, M., Bautista, F., Meazza, C., Janeway, K., Dela Cruz, F.S., Whittle, S., Morgenstern, D.A., Dutta, L., McKenzie, J., O'Hara, K., Huang, J., Okpara, C.E., Bidadi, B., Koh, K-N., Moreland, B.

Source: In Annals of Oncology November 2020 31 Supplement 6:S1414-S1415

1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)

Authors: Gaspar, N., Campbell-Hewson, Q., Bielack, S.S., Campbell, M., Bautista, F., Meazza, C., Janeway, K., Dela Cruz, F.S., Whittle, S.B., Morgenstern, D.A., Dutta, L., McKenzie, J., O'Hara, K., Huang, J., Okpara, C.E., Bidadi, B., Koh, K-N., Morland, B.

Source: In Annals of Oncology September 2020 31 Supplement 4:S990-S991

316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study

Authors: Cohen, E., Uppaluri, R., Lee, N., Westra, W., Haddad, R., Temam, S., Le Tourneau, C., Chernock, R., Safina, S., Tao, Y., Klochikhin, A., Meirovitz, A., Brana, I., Ge, J.Y., Swaby, R., Bidadi, B., Adkins, D.

Source: In Annals of Oncology November 2019 30 Supplement 9:ix106-ix106

1121TiP - KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)

Authors: Machiels, J.-P., Licitra, L., Tao, Y.G., Yen, C.-J., Rischin, D., Waldron, J.N., Burtness, B.A., Gregoire, V., Agarwala, S.S., Yorio, J., Delord, J.-P., Aksoy, S., Ikeda, S., Hong, R.-L., Ge, J.Y., Brown, H., Bidadi, B., Siu, L.L.

Source: In Annals of Oncology October 2018 29 Supplement 8

96TiP - Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)

Authors: Machiels, J-P, Yen, C-J, Licitra, L., Rischin, D., Waldron, J., Burtness, B., Gregoire, V., Tao, Y.G., Yorio, J., Aksoy, S., Ikeda, S., Hong, R-L, Ge, J.Y., Brown, H., Bidadi, B., Siu, L.

Source: In Annals of Oncology December 2017 28 Supplement 11:xi28-xi28

373TiP - KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)

Authors: Yen, C-J, Machiels, J-P, Licitra, L., Rischin, D., Waldron, J., Burtness, B., Gregoire, V., Tao, Y., Yorio, J., Aksoy, S., Ikeda, S., Hong, R-L, Ge, J.Y., Brown, H., Bidadi, B., Siu, L.

Source: In Annals of Oncology November 2017 28 Supplement 10:x110-x110

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC).

Authors: Machiels, J.P.¹ (AUTHOR), TAO, Y.² (AUTHOR), Burtness, B.^1,3 (AUTHOR), Tahara, M.⁴ (AUTHOR), Rischin, D.⁵ (AUTHOR), Alves, G.V.⁶ (AUTHOR), Lima, I.P. Figueiredo⁷ (AUTHOR), Hughes, B.G.M.⁸ (AUTHOR), Pointreau, Y.⁹ (AUTHOR), Aksoy, S.¹⁰ (AUTHOR), Laban, S.¹¹ (AUTHOR), Greil, R.¹² (AUTHOR), Burian, M.¹³ (AUTHOR), Hetnal, M.¹⁴ (AUTHOR), Licitra, L.¹⁵ (AUTHOR), Black, C.M.¹⁶ (AUTHOR), Norquist, J.¹⁶ (AUTHOR), Gumuscu, B.¹⁶ (AUTHOR), Bidadi, B.¹⁶ (AUTHOR), Siu, L.L.¹⁷ (AUTHOR)

Source: International Journal of Radiation Oncology, Biology, Physics. Apr2024, Vol. 118 Issue 5, pe39-e40. 2p.

Subject Terms: *HEAD & neck cancer, *SQUAMOUS cell carcinoma, *QUALITY of life, *PHYSICAL mobility, *CHEMORADIOTHERAPY, *SYMPTOMS

Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study.

Authors: Harrington, K.¹ (AUTHOR), Kim, H.R.² (AUTHOR), Salas, S.³ (AUTHOR), Oliva, M.⁴ (AUTHOR), Metcalf, R.⁵ (AUTHOR), Bernsdorf, M.⁶ (AUTHOR), Kim, J.W.⁷ (AUTHOR), Cohen, E.⁸ (AUTHOR), Siu, L.L.⁹ (AUTHOR), Rischin, D.¹⁰ (AUTHOR), Licitra, L.¹¹ (AUTHOR), Vermorken, J.¹² (AUTHOR), Le, Q.T.¹³ (AUTHOR), Tahara, M.¹⁴ (AUTHOR), Machiels, J.P.¹⁵ (AUTHOR), O'Hara, K.¹⁶ (AUTHOR), Pathiraja, K.¹⁷ (AUTHOR), Gumuscu, B.¹⁷ (AUTHOR), Bidadi, B.¹⁷ (AUTHOR), Burtness, B.^1,18 (AUTHOR)

Source: International Journal of Radiation Oncology, Biology, Physics. Apr2024, Vol. 118 Issue 5, pe42-e42. 1p.

Subject Terms: *SQUAMOUS cell carcinoma, *IMMUNOTHERAPY, *CANCER chemotherapy, *PEMBROLIZUMAB, *PLATINUM

Sequential Treatment Use in Clinical Practice for U.S. Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC).

Authors: Zheng, D.¹ (AUTHOR), Black, C.M.¹ (AUTHOR), Hair, G.M.¹ (AUTHOR), Bidadi, B.¹ (AUTHOR), Lerman, N.¹ (AUTHOR), Ai, L.¹ (AUTHOR), Zion, A.² (AUTHOR), Zou, L.² (AUTHOR), Gao, W.² (AUTHOR), Hanna, G.J.³ (AUTHOR)

Source: International Journal of Radiation Oncology, Biology, Physics. Apr2024, Vol. 118 Issue 5, pe34-e34. 1p.

Subject Terms: *HEAD & neck cancer, *SQUAMOUS cell carcinoma, *FRAIL elderly, *OROPHARYNGEAL cancer, *COMBINATION drug therapy, *NECK